HALO
HALOZYME THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$122.50
+0.54%Margins
Gross margin
82.4%
EBITDA margin
43.2%
EBIT margin
55.9%
Net margin
24.9%
FCF margin
48.5%
288.1%
Return on equity
16.0%
Return on assets
40.6%
Return on invested capital
0.63x
Asset turnover
$818.6M
Cash from operations
$2.04
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026